These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8866502)

  • 1. Acute pharmacologic blockade of dyskinesias in Parkinson's disease.
    Blanchet PJ; Metman LV; Mouradian MM; Chase TN
    Mov Disord; 1996 Sep; 11(5):580-1. PubMed ID: 8866502
    [No Abstract]   [Full Text] [Related]  

  • 2. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; Blanchet PJ; van den Munckhof P; Chase TN
    Amino Acids; 1998; 14(1-3):75-82. PubMed ID: 9871445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.
    Muenter MD
    Neurology; 1970 Dec; 20(12):Suppl:6-13. PubMed ID: 4921587
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological strategies for controlling motor fluctuations in Parkinson's disease.
    Ruggieri S; Carta A; Stocchi F; Antonini A; Bellantuono P; Monge A
    Funct Neurol; 1988; 3(4):471-9. PubMed ID: 3072281
    [No Abstract]   [Full Text] [Related]  

  • 8. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
    Filipović SR; Rothwell JC; van de Warrenburg BP; Bhatia K
    Mov Disord; 2009 Jan; 24(2):246-53. PubMed ID: 18951540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
    Leroi I; Overshott R; Byrne EJ; Daniel E; Burns A
    Mov Disord; 2009 Jun; 24(8):1217-21. PubMed ID: 19370737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of pure akinesia due to Lewy body parkinson's disease with pathology.
    Imai H; Narabayashi H
    Mov Disord; 1990; 5(1):90-1. PubMed ID: 2296268
    [No Abstract]   [Full Text] [Related]  

  • 12. Depression treatment in Parkinson's disease.
    Driver PS
    DICP; 1991 Feb; 25(2):137-8. PubMed ID: 2058186
    [No Abstract]   [Full Text] [Related]  

  • 13. Which factors influence therapeutic decisions in Parkinson's disease?
    Baas H; Fuchs G; Gemende I; Hueber R; Lachenmayer L; Schneider E; Schoenberger B; Werner M
    J Neurol; 2002 Oct; 249 Suppl 3():III/49-52. PubMed ID: 12522573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
    Merello M; Nouzeilles MI; Cammarota A; Leiguarda R
    Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.
    Olanow CW; Gracies JM; Goetz CG; Stoessl AJ; Freeman T; Kordower JH; Godbold J; Obeso JA
    Mov Disord; 2009 Feb; 24(3):336-43. PubMed ID: 19006186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Two cases of buccolingual dyskinesia treated with tiapride (author's transl)].
    Robillard J
    Sem Hop; 1980 Nov 8-15; 56(41-42):1731-2. PubMed ID: 6255602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
    Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.
    Lou JS; Kearns G; Benice T; Oken B; Sexton G; Nutt J
    Mov Disord; 2003 Oct; 18(10):1108-14. PubMed ID: 14534913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.